Market observation of slimming drugs: development and approval of regular slimming drugs accelerate

Source: qinyi 2015-01-27 with the continuous improvement of people's living standards and changes in living habits, obesity has become a global health problem Moreover, many diseases caused by obesity, such as heart disease, hypertension and so on, have gradually become a major public health problem The development of more effective, side effects of weight-loss drugs is also growing voice In 2012, the U.S Food and Drug Administration opened a green channel for weight-loss drugs for the first time in 13 years and approved belviq, a weight-loss drug owned by arena Since then, the FDA has successively passed the approval of several weight-loss drugs, and the speed of approval has increased unabated The research and development of weight-loss drugs has ushered in a rare opportunity The author of the following in the latest research or development of successful weight-loss drugs and weight-loss drugs market problems In June 2014, it was reported that the weight-loss drug gelesis100 under the biotechnology company gelesis had entered the stage of approval for listing It is reported that obese patients only need to take a small dose of gelesis100 before meals to achieve the ideal effect of weight loss But because the company's data on the drug seems to be too standard, the drug is not favored by many experts This leaves a relatively large space for the approval of more weight-loss drugs On September 11, 2014, orexigen collected the clinical research safety data of more than 10000 patients who had been treated by its weight-loss drug contract for three years, and finally got the approval of FDA to go on the market, realizing the "counter attack" And just a day later, competitor liraglutide, a weight-loss drug owned by Novo Nordisk, won a huge majority of votes from the FDA Expert Committee and entered the golden development period Liraglutide, as a GLP-1 analog, can promote insulin secretion through GLP-1 receptor binding Long term observation shows that liraglutide can effectively reduce the weight of patients It is an ideal weight-loss drug, and the market recognition is also very high Therefore, in December 2014, liraglutide, under the trade name saxenda, obtained the FDA listing license for weight-loss drugs, and became a new heavy-duty drug in the weight-loss drug market In addition to the above FDA approved drugs, in January 2015, the mid-term study of belloranib, a obesity drug under zafgen, which specializes in the treatment of hypothalamic injury, obtained ideal results and further safety certification Zafgen claims that the blood lipid content and inflammatory symptoms of patients treated with belloranib can be significantly improved, which is a potential weight-loss drug And zagen did not meet this requirement, saying that it is actively carrying out the three-phase clinical development of belloranib for the treatment of Puda Willi syndrome As one of the rare diseases, prada Willi syndrome can make people feel hungry and overeat, leading to obesity If this research is successful, belloranib will undoubtedly occupy an irreplaceable position in the weight-loss drug market According to another report, recently American scientists invented a special weight-loss drug called "fexaramine", which can activate the human protein molecule "FXRs", let the body release bile acid, change the blood sugar level, inhibit people's appetite, start the food processing mechanism, and "burn" human fat, so as to achieve the effect of weight loss Moreover, the side effects of "fexaramine" were significantly reduced compared with other appetite suppressing drugs Because it has no effect on other organs except human intestinal tract Therefore, the development prospect of fexaramine is very considerable In China, there are also some outstanding weight-loss drugs, such as Sunan pharmaceutical, which has recently been approved for marketing, is the first OTC weight-loss drug in the world, and the only non central nervous function weight-loss drug so far Because it has many advantages such as high safety, no effect with central nervous system, no need of blood circulation process, no influence on appetite and so on, it has a good response in our market With the improvement of people's living standards and the change of living habits, obesity has become a global health problem Moreover, many diseases caused by obesity, such as heart disease, hypertension and so on, have gradually become a major public health problem The development of more effective, side effects of weight-loss drugs is also growing voice However, it is worth mentioning that because of the particularity of obesity treatment itself, the market of slimming drugs is relatively mixed For example, in 2008, the FDA blacklisted 28 weight-loss drugs In 2013, the FDA recalled the weight-loss drugs containing fat reducing essence In June 2014, the FDA investigated some weight-loss drugs with "pollen weight-loss" as the selling point and illegally added sibutramine and phenolphthalein The occurrence of these events, to a certain extent, requires our government to strengthen the management of weight-loss drug market, and also reminds us that obese people must be careful when choosing drugs